Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.59 |
| ▸ | HTR1A | P08908 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661355 | 1.00 | PARP1 (0.59) | PARP1HTR1ASLC6A4NR3C1PGR | |
| SCHEMBL6635190 | 0.89 | PARP1 (0.47) | PARP1HTR1ASLC6A4 | |
| SCHEMBL12078457 | 0.79 | PARP1 (0.58) | PARP1HTR1ASLC6A4NR3C1PGR | |
| SCHEMBL4100100 | 0.76 | PARP1 (0.39) | PARP1NR3C1PGRNR3C2DYRK1A | |
| SCHEMBL2464027 | 0.76 | PARP1 (0.39) | PARP1NR3C1PGRNR3C2DYRK1A | |
| SCHEMBL30467095 | 0.76 | PARP1 (0.39) | PARP1NR3C1PGRNR3C2DYRK1A | |
| SCHEMBL30768351 | 0.76 | PARP1 (0.39) | PARP1NR3C1PGRNR3C2DYRK1A | |
| SCHEMBL4107808 | 0.76 | PARP1 (0.39) | PARP1DYRK1A | |
| SCHEMBL30695888 | 0.76 | PARP1 (0.39) | PARP1DYRK1A | |
| SCHEMBL7479006 | 0.76 | PARP1 (0.59) | PARP1HTR1ASLC6A4NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147083-B1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6465482-B2 | ANTIDEPRESSANTS; ANXIOLYTIC AGENTS; SEROTONIN-AFFECTED NERVOUS SYSTEM DISORDERS; ACTING AT THE 5-HT1A AUTORECEPTORS CONCOMMITANTLY WITH 5-HT TRANSPORTERS; ANTISEROTONIN AGENTS; SEROTONIN REUPTAKE INHIBITORS; HT3 RECEPTOR ANTAGONISTS | WYETH | 2002-10-15 | — | — | US | disclosed |
| US-20020045628-A1 | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-18 | — | — | US | disclosed |
| US-6313126-B1 | FOR THRERAPY OF DISORDERS ASSOCIATED WITH DYSFUNCTION IN SEROTONERGIC NEUROTRANSMISSION, INCLUDING DEPRESSION AND ANXIETY | AMERICAN HOME PRODUCTS CORP | 2001-11-06 | — | — | US | disclosed |
| EP-1147083-A1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000040554-A1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045628-A1 | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression | HTR2C, TPH1, TPH2 | PARP1 2402/4885HTR1A 9/4885SLC6A4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.